Erasca Finalizes $225M Public Offering at $10.00/Share
Summary
Erasca has priced its upsized public offering of 22.5 million shares at $10.00 per share, with expected gross proceeds of $225 million. The offering, which finalizes terms announced on January 20, 2026, will fund research and development efforts.
Key Events
-
Public Offering Priced
Erasca priced its public offering of 22.5 million shares at $10.00 per share, raising $225 million in gross proceeds.
-
Underwriting Agreement
The company entered into an underwriting agreement with J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Jefferies LLC, and Evercore Group L.L.C.
-
Use of Proceeds
Erasca intends to use the net proceeds to fund research and development, working capital, and other general corporate purposes.
Analysis
Erasca has finalized the terms of its public offering, initially announced on January 20, 2026. The offering consists of 22.5 million shares at $10.00 per share, raising $225 million before deductions. This capital raise strengthens Erasca's balance sheet, providing resources for ongoing research and development.
At the time of this filing, ERAS was trading at $10.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.9B. The 52-week trading range was $1.01 to $10.67. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.